Table 2 Summary of the clinical trial demographic characteristics
Traditional group sequential design (n = 43) | Adaptive design (n = 13) | |||
|---|---|---|---|---|
No. | Percentages | No. | Percentages | |
Funders | ||||
Public | 9 | 20.9% | 2 | 15.4% |
Commercial (company) | 33 | 76.7% | 11 | 84.6% |
None | 1 | 2.3% | 0 | 0 |
Country (chief investigator) | ||||
USA | 18 | 41.9% | 10 | 76.9% |
European | 13 | 30.2% | 3 | 23.1% |
Others* | 12 | 27.9% | 0 | 0 |
Centres/sites | ||||
1 | 2 | 4.7% | 1 | 7.7% |
2–49 | 5 | 11.6% | 3 | 23.1% |
50–99 | 8 | 18.6% | 4 | 30.8% |
100–199 | 6 | 14% | 2 | 15.4% |
200–299 | 4 | 9.3% | 2 | 15.4% |
300–499 | 4 | 9.3% | 0 | 0 |
500–799 | 7 | 16.3% | 1 | 7.7% |
800-1,100 | 7 | 16.3% | 0 | 0 |